Catalytic Wealth RIA LLC Has $372,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Catalytic Wealth RIA LLC raised its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 20.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,171 shares of the company’s stock after buying an additional 4,468 shares during the quarter. Catalytic Wealth RIA LLC’s holdings in Takeda Pharmaceutical were worth $372,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of TAK. Millennium Management LLC raised its holdings in shares of Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after purchasing an additional 2,023,707 shares during the period. Van ECK Associates Corp boosted its holdings in Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after acquiring an additional 134,407 shares in the last quarter. Cowen AND Company LLC acquired a new stake in Takeda Pharmaceutical in the second quarter valued at approximately $6,866,000. Summit Global Investments increased its holdings in shares of Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after acquiring an additional 192,143 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Takeda Pharmaceutical by 6.7% during the first quarter. Sei Investments Co. now owns 372,975 shares of the company’s stock worth $5,181,000 after purchasing an additional 23,525 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $13.66 on Tuesday. The stock has a market cap of $43.45 billion, a P/E ratio of 23.66, a P/E/G ratio of 0.26 and a beta of 0.54. The business’s fifty day moving average is $14.38 and its 200 day moving average is $13.82. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.